Nineschizophrenic inpatients were studied under haloperidol treatment for the purpose of evaluating the possible correlation between plasma HVA, leuels(P-HVA) plasma haloperidol levels (P-haloperidal) and clinical symptom changes. The authors
measured
plasma HVA and plasma haloperidol levels, and checked BPRS and SAPS scores at baseline. 7th day, 28th day and 56th day of treatment.
1) P-HVA concentrations of total patients were highest on 7th day, then returned to baseline levels on 28th day, but that of drug responder group(6 patients) were highest on pretreatment then decreased below baseline levels on 7th day and
continued to
decrease till 56th day of treatment.
2) P-HVA concentration of total patients showed positive correlations with BPRS scores (r=0.28, p<0.1) and with SAPS scores(r=0.36, p<0.05) and that of drug responder group showed also positive correlations with BPRS scores(r=0.24, p=NS) and
with
SAPS
scores (r=0.45, p<0.01).
3) P-haloperidol concentrations of total patients showed significant positive correlation with haloperidol doses(r=0.73, p<0.001) and that of drug responder group showed positive correlation with haloperidol doses(r=0.53. P<0.01). P-haloperidol
concentration of drug responder group showed significant negative correlation with BPRS scores(-0.72, P<0.01) and with SAPS scores(-0.59. P<0.001) but that of total patients did not.
4) The haloperidol doses of drug responder group showed meaningful negative correlations with P-HVA(r=-0.38, p=0.03) and with BPRS scores(r=-0.50, P<0.01) and with SAPS scores(r=-0.47, p=0.01) but that of total patients did not.
The authors discussed the meaning of above results.
|